Microbot Medical confirms no business disruption amid Middle East events, progresses LIBERTY commercial launch

Microbot Medical Inc.

No business disruption in USA or Israel; all personnel operational, lead manufacturing partner fully functional.
LIBERTY system received FDA clearance; limited market release began late 2025; full market release at SIR April 2026.
Hired additional U.S. sales representatives and a Director of Health Economics and Outcomes Research (HEOR) for commercial expansion.
Sufficient U.S. inventory maintained; building additional stock via third-party logistics partner for anticipated demand.

item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001493152-26-008658
form_type: 8-K
ticker: MBOT
cik: 0000883975
company_name: Microbot Medical Inc.
filed_at: 2026-03-03T23:59:59+00:00
discovered_at: 2026-05-14T18:02:37.910887+00:00
generated_at: 2026-05-15T22:28:10.606557+00:00
sec_items: ["7.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.5
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001493152-26-008658
json_url: https://secwatch.observer/filing/0001493152-26-008658.json
markdown_url: https://secwatch.observer/filing/0001493152-26-008658.md
text_url: https://secwatch.observer/filing/0001493152-26-008658.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/883975/000149315226008658/0001493152-26-008658-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/883975/000149315226008658/form8-k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001493152-26-008658

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.